28 April,2021 06:09 PM IST | Pune | mid-day online correspondent
File Pic
Serum Institute of India's CEO, Adar Poonawalla, on Wednesday, announced that Covishield's price for states will be slashed from Rs 400 to Rs 300 as a philanthropic gesture.
Taking to Twitter, Poonawalla said, "As a philanthropic gesture on behalf of @SerumInstIndia, I hereby reduce the price to the states from Rs.400 to Rs.300 per dose, effective immediately; this will save thousands of crores of state funds going forward. This will enable more vaccinations and save countless lives."
ALSO READ
‘Misguided, forced to take Covid vaccines’
Demand for compensation for injuries, deaths allegedly caused by Covid vaccines
Trump chooses anti-vaccine activist Robert F. Kennedy Jr. as health secretary
Trump expected to choose vaccine skeptic Robert F. Kennedy Jr. as health secretary: AP sources
PopVax Announces that the U.S. National Institute of Allergy and Infectious Diseases will Conduct and Sponsor the U.S.-based Phase I Clinical Trial of PopVax’s Next-Generation mRNA-LNP COVID-19 Vaccine as part of the U.S. Government’s Project NextGen
Covishield's price for private hospitals remains at Rs 600 per dose.
This follows widespread criticism of its pricing policy as it had sold the initial doses of Covishield to the central government at Rs 150 per dose.
Both Bharat Biotech and Serum's vaccines are available to the central government at a rate of Rs 150 per dose.
